Clinical Trial Detail

NCT ID NCT03280563
Title A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements yes
Sponsors Hoffmann-La Roche
Indications

Her2-receptor negative breast cancer

Therapies

Atezolizumab + Ipatasertib

Atezolizumab + Bevacizumab + Exemestane

Atezolizumab + Cobimetinib

Atezolizumab + Bevacizumab + Fulvestrant

Atezolizumab + Bevacizumab + Tamoxifen

Atezolizumab + Ipatasertib + Fulvestrant

Fulvestrant

Atezolizumab + Fulvestrant

Age Groups: senior adult

Additional content available in CKB BOOST